Accessibility Menu
Curaleaf logo

Curaleaf(OTC) CURLF

Market Cap$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-51%
5 Year-73%
1 Year-4%
1 Month+16%
$9.66
+3.21%
+0.30Today
Curaleaf last closing stock price
MetricPriceDate
Last closeUSD 9.662026-08-28
Curaleaf stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.3%USD 9.992026-08-21
1 month+15.55%USD 8.362026-07-29
3 month-8.13%USD 10.522026-05-29
Year to date+27.78%USD 7.562025-12-31
1 year-4.45%USD 10.112025-08-28
3 year+19.7%USD 8.072023-08-29
5 year-73.37%USD 36.272021-08-27
Since inception-50.91%USD 19.682018-10-30

Curaleaf Financials at a Glance

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.31B

Net Income (TTM)

-$36.45M

EPS (TTM)

-$0.18

P/E Ratio

-54.00

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$9.66

Volume

172,222

Open

$9.59

Previous Close

$9.66

Daily Range

$9.22 - $9.81

52-Week Range

$5.40 - $15.15

Estimated Earnings Date

Nov 4, 2026

CURLF News

Person using a vaping product

Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?

Eric VolkmanAug 20, 2026
A cannabis leaf on top of a $100 bill.

5 Best Cannabis ETFs for 2026 and How to Invest

Keith SpeightsAug 12, 2026
A person trimming a cannabis plant.

Is Acquiring Aurora Cannabis a Good Move for Curaleaf?

David Jagielski, CPAAug 12, 2026
Person in lab gear working with marijuana plants.jpg

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

Eric VolkmanAug 12, 2026
GettyImages-1477090373-1200x800-5b2df79

Better Buy: Green Thumb Industries vs. Curaleaf Holdings

Thomas NielJun 1, 2026
An excited investor looking at a chart.

3 Cannabis Stocks That Could Soar After Marijuana Rescheduling

David Jagielski, CPAApr 28, 2026
Person using a vaping product

Why Curaleaf Holdings Stock Popped by Almost 25% on Tuesday

Eric VolkmanDec 16, 2025
Smiling person in a grow room full of marijuana plants

Why Investors Were Buzzing About Curaleaf Stock Today

Eric VolkmanDec 4, 2025
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Curaleaf

Curaleaf Holdings, Inc. is a leading cannabis company engaged in the retail and wholesale of cannabis products across the United States and internationally. The company operates licensed cultivation and pharma-grade cannabis processing facilities, supplying products to various markets including Australia, New Zealand, and several European countries.

Products and Services
  • Wide range of cannabis products for medical and adult-use markets
  • Retail and wholesale distribution channels
  • Pharma-grade cannabis processing and manufacturing facilities
Growth Outlook
  • Expansion into international markets enhances revenue potential
  • Increasing demand for cannabis products supports long-term growth
  • Strategic acquisitions may drive market share and operational efficiency
Financial Highlights
  • Q2 2026 revenue of $336.7 million, up from $319.7 million in Q1 2026
  • Gross profit margin improved to 50.5% in Q2 2026
  • Net income of $12.4 million reported in Q2 2026, a positive shift from previous quarters
Curaleaf Holdings, Inc. has established itself as a significant player in the cannabis industry, with a robust operational framework and a diverse product portfolio. The company's strategic focus on expanding its market presence, both domestically and internationally, positions it well for future growth. Recent financial performance indicates a positive trend, with increasing revenues and improved profit margins. The ability to adapt to market demands and regulatory changes will be crucial for sustaining growth and enhancing shareholder value.
AI Generated • Aug 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,554

CEO

Boris Alexis Jordan

Website

www.curaleaf.com

Headquarters

Stamford, CT 06902, US

CURLF Financials

Key Financial Metrics (TTM)

Gross Margin

44.10%

Operating Margin

0.91%

Net Income Margin

-2.77%

Return on Equity

-4.47%

Return on Capital

1.45%

Return on Assets

-1.30%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

-0.05%

Stock Overview

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

264.81M

Volume

172.22K

Avg. Volume

209.85K

Financials (TTM)

Gross Profit

$579.92M

Operating Income

$11.96M

EBITDA

$144.20M

Operating Cash Flow

$140.67M

Capital Expenditure

-$64.47M

Free Cash Flow

$76.20M

Cash & ST Invst.

$106.97M

Total Debt

$1.11B

Curaleaf Performance Analysis

Curaleaf annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,275,420,0006.6%
20232023-12-31USD 1,346,632,0005.6%
20242024-12-31USD 1,334,299,000-0.9%
20252025-12-31USD 1,268,135,000-5.0%
Curaleaf sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.2%
Q42025-12-315.6%
Q12026-03-31-5.5%
Q22026-06-305.3%
Curaleaf annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.5676.6%
20232023-12-31USD -1.17-25.4%
20242024-12-31USD -0.96-17.2%
20252025-12-31USD -1.0811.6%
Curaleaf sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.2%
Q42025-12-31-6.8%
Q12026-03-31214.4%
Q22026-06-30-81.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$336.72M

+5.3%

Gross Profit

$169.91M

+42.9%

Gross Margin

50.46%

N/A

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$460.58K

N/A

Employees

5,554

N/A

Net Income

$12.48M

+123.1%

EBITDA

$22.32M

-64.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$106.97M

+4.4%

Total Debt

$1.11B

+32.2%

Accounts Receivable

$82.28M

+13.8%

Inventory

$244.72M

+7.8%

Long Term Debt

$1.03B

+34.5%

Short Term Debt

$86.74M

+10.1%

Return on Assets

-1.30%

N/A

Return on Invested Capital

0.48%

N/A

Free Cash Flow

$12.96M

+242.7%

Operating Cash Flow

$28.49M

+360.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCNNFTrulieve Cannabis Corp.
$11.07+0.39%
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
LBTSFAlmirall, S.A.
$15.35-0.78%
CASBFCanSino Biologics Inc.
$4.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About CURLF

What is the current price of Curaleaf?

Curaleaf is trading at $9.66 per share.

What is the 52-week range for Curaleaf?

Over the past 52 weeks, Curaleaf has traded between $5.40 and $15.15.

How much debt does Curaleaf have?

As of the most recent reporting period, Curaleaf reported total debt of $1.11B.

How much cash does Curaleaf have on hand?

Curaleaf reported $106.97M in cash and cash equivalents in its most recent financial results.

What is Curaleaf’s dividend yield?

Curaleaf does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services